Logo for University of Iowa Health Care This logo represents the University of Iowa Health Care

Dean's List: New Funding Awards

Notable & novel scientific awards to celebrate. 

2021: JanuaryFebruary, March, April, May, June, July, August, September

SEPTEMBER 2021

Competitive Renewal

Val Sheffield Ophthalmology and Visual Sciences NIH P30 - 5 years  Multidisciplinary Investigations in Visual Science

New Federal Awards

Dale Abel
Long-Sheng Song
Internal Medicine NIH R01 - 4 years Molecular Determinants of MG53 in heart structure and function
Angelo Antiguas Anatomy and Cell Biology NIH F31 - 3 years Function of IRF6 in regulating E-cadherin dependent adherens junctions
Dustin Bosch Pathology NIH K08 - 5 years Contact-dependent interbacterial responses modulate intestinal colonization by Bacteroides species
Noah Butler Microbiology and Immunology NIH R01 - 5 years Mechanisms and consequences of extrafollicular B cell activation during malaria
Duane Hall Internal Medicine NIH R01 - 4 years ERK1/2-Integrin Signaling in Desmosome-Dyad Crosstalk
Ali Jabbari Dermatology NIH R01 - 5 years IL-27 and downstream mechanisms in alopecia areata
Bing Li Pathology NIH R01 Transfer - 5 years E-FABP mediates n-3 fatty acid-induced tumor prevention through epigenetic control of immune cell differentiation and function
Catherine Marcinkiewcz Neuroscience and Pharmacology NIH R01 - 5 years Sleep and affective disturbances in the etiology of Alzheimer's disease

Other Awards

Janet Fairley Dermatology Calabetta Bio A phase 1, open-label, safety and dosing study of autologous desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in subjects with active, anti-DSG3, mucosal-dominant pemphigus vulgaris
Muhammad Furqan Internal Medicine PPD Investigator Services, LLC A Randomized, Parallel-Group Treamtent, Phase 2/3, Open-Label, 3-Arm Study Comparing Efficacy of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to  Docetaxel Alone in Male and Female Participants Aged 18 years and Older with Advanced Non-Sm
Katherine Mathews Pediatrics FIbroGen, Inc A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination with Systemic Corticosteroids in Subjects with Non-ambulatory Duchenne Muscular Dystrophy (DMD
Mohammed Milhem Internal Medicine TopAlliance Biosciences, Inc A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 in Subjects with Advanced Solid Malignancies including Lymphoma
Sidakpal Panaich Internal Medicine Edwards Lifesciences, LLC PASCAL CLASP IID/IIF Pivotal Clinical Trial
Huy Tran Internal Medicine Alnylam Pharmaceuticals, Inc A Phase 1, Randomized, Double-Blind, Placebo- Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients with Nonalcoholic Steat

Top of Page

AUGUST 2021

New Federal Awards

Hongshuai Li Orthopaedics and Rehabilitation NIH R01 - 4 years Targeting Nitrate-Nitrite-NO pathway for Ameliorating Muscle and Bone Comorbidities in Duchenne Muscular Dystrophy
Dominique Limoli Microbiology and Immunology NIH R35 - 5 years Decoding interspecies signaling networks and the biogeography of polymicrobial infections
Nandakumar Narayanan Neurology DoD, CDMRP - 3 years PD200037 - Prefrontal microcircuits and cognitive symptoms of Parkinson's disease
Katerina Sosa Neurology NIH F31 - 2 years Sex Differences in Susceptibility to SUDEP: Potential Role of Sex Steroids
Maria Spies Biochemistry and Molecular Biology NIH S10 - 1 year Lumick's C-Trap instrument for single-molecule analysis of macromolecular dynamics
Lane Strathearn
Ted Abel
Pediatrics
Neuroscience and Pharmacology
NIH P50 - 5 years University of Iowa Hawkeye Intellectual and Developmental Disabilities Research Center (HAWK-IDDRC)
Budd Tucker
Elaine Binkley
Robert Mullins
Ophthalmology and Visual Sciences NIH R21 - 2 years R21 VHL - Molecular Pathophysiology of Von Hippel Lindau (VHL) disease
John Wemmie Psychiatry NIH R01 - 5 years Novel mechanisms for correcting opioid-induced synaptic abnormalities

Other Awards

Alejandro Comellas Internal Medicine Gala Therapeutics, Inc A Clinical Evaluation of the RheOx Bronchial Rheoplasty System for the Treatment of the Symptoms of Chronic Bronchitis in Adult Patients with COPD
Rohan Garje Internal Medicine Immunomedics, Inc A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer
Pashtoon Kasi Internal Medicine Seagen, Inc MOUNTAINEER-02: Tucatinib, trastuzumab, ramucirumab, and paclitaxel versus paclitaxel and ramucirumab in previously treated HER2+ gastroesophageal cancer
Sneha Phadke Internal Medicine Genentech, Inc A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk fo Recurrence
Praveen Vikas Internal Medicine Sanofi US Services, Inc A Randomized, Multicenter, Double-blind, Phase 3 Study of SAR439859 plus Palbociclib Versus Letrozole plus Palbociclib for the Treatment of Patients with ER (+), HER2 (-) Breast Cancer who have not Received any Prior Systemic Anti-Cancer Treatment for Adv
Patricia Winokur Internal Medicine Pfizer, Inc A Phase 3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of Respiratory Syncytial Virus (RSV) Prefusi on F Subunit Vaccine in Adults
Yousef Zakharia Internal Medicine Astellas Pharmac, Inc A Phase 1/2, Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP7517 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Known to Express WT1 Antigen
Yousef Zakharia Internal Medicine Seattle Genetics, Inc. A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment

Top of Page

JULY 2021

Competitive Renewal

Marlan Hansen Otolaryngology NIH T32 - 5 years Research Training Program in Otolaryngology

New Federal Awards

Gail Bishop Microbiology and Immunology NIH R01 - 4 years Regulation of B cell signaling in autoimmunity by TRAF3
David Kaczka Anesthesia DoD, CDMRP - 3 years Preclinical Evaluation of Multi-Frequency Oscillatory Ventilation in a Large Animal Model of Acute Respiratory Failure
Damian Krysan Pediatrics NIH R01 - 5 years Discovery and development of antifungal acetyl CoA synthetase inhibitors
George Richerson Neurology NIH R01 - 5 years Prevention of SUDEP by milk whey: Role of CO2 chemoreception and serotonin
Rasna Sabharwal Internal Medicine NIH 1 R21 - 2 years RAS-Driven Central Inflammation and Cognitive Decline with Aging.
Dong Rim Seol Orthopaedics and Rehabilitation NIH R03 - 2 years Exosome-based Cell Homing and Lineage-Specific Differentiation Strategies for Dental Pulp Regeneration
Douglas Spitz
Val Sheffield
Radiation Oncology NIH R21 - 2 years Evaluation of Orthogonally Oriented Electromagnetic Fields to Stabilize ROS, Induce DNA damage and Improve Survival in Non-Small Cell Lung Cancer
Michael Wright Molecular Phyusiology and Biophysics NIH 1 R01 - 4 years Construction of the Androgen Receptor Interactome: A Molecular Framework for Probing Genetic Interactions in Androgen-Dependent Signaling

Other Awards

Muhammad Furqan Internal Medicine PPD Investigator Services, LLC A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinu
Nabeel Hamzeh Internal Medicine Genentech, Inc A Phase III Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients with Idiopathic Pulmonary Fibrosis
Sharon Larson Surgery CryoLife, Inc A prospective, randomized, active (warfarin) controlled, parallel-arm clinical trial to determine if patients with and On-X aortic valve can be maintained safely and effectively on the factor Xa inhibitor apixaban
Katherine Mathews Pediatrics FIbroGen, Inc A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination with Systemic Corticosteroids in ambulatory subjects with Duchenne Muscular Dystrophy (DMD
Sidakpal Panaich Internal Medicine Edwards Lifesciences, LLC Edwards PASCAL CLASP II TR Pivotal Clinical Trial
Patricia Winokur Internal Medicine Pfizer, Inc A Study to Evaluate Additional Dose(s) of BNT162b2 in Healthy Individuals  Previously Vaccinated With BNT162b2

Top of Page

JUNE 2021

Competitive Renewal

Mary Wilson Microbiology and Immunology NIH T32 - 5 years Training in Mechanisms of Parasitism

New Federal Awards

Jane Buchanan Molecular Phyusiology and Biophysics NIH F30 - 3 years Muscle Mitochondrial Pyruvate Carrier Disruption Alters Amino Acid Metabolism to Maintain Muscle Mass During Recovery from Obesity
Rebecca Dodd Internal Medicine DoD, CDMRP - 3 years NF200067 - Targeting a pro-tumorigenic immunosuppressive loop in MPNST            
Oliver Gramlich Ophthalmology and Visual Sciences NIH R21 - 2 years In vivo modeling of autoantibody-induced optic neuritis
David Hughes Internal Medicine NIH K01 - 5 years The role of Fbxl22 in the regulation of skeletal muscle mass
Damian Krysan Pediatrics NIH R21 - 2 years Hit-to-lead optimization of broad spectrum antifungal phenothiazines
Steven Lentz Medicine Administration NIH T32 - 5 years Medical Scientist Training Program
Merry Mani Radiology NIH R01 - 4 years Fast Multi-dimensional Diffusion MRI with Sparse Sampling and Model-based Deep Learning Reconstruction
Kelly Messingham Dermatology NIH R03 - 2 years Generation of IgG and IgE autoantibodies in an active mouse model of Bullous pemphigoid
Sabrina Scroggins Obstetrics and Gynecology NIH K01 - 5 years Testing the efficacy of regulatory dendritic cell treatment in the prevention of preeclampsia
Nicholas Trapp Psychiatry NIH K23 - 5 years Investigating Network Plasticity Effects of Repetitive Brain Stimulation Following Invasive and Noninvasive Methods in Humans

Other Awards

John Bernat Pediatrics Travere Therapeutics, Inc A Phase 3 Study to Evaluate the Effects of Chenodal in Adult and Pediatrics Patients with Cerebrotendinous Xanthomatosis
Linda Cadaret Internal Medicine Endotronix, Inc PROACTIVE-HF
Joseph Caster Radiation Oncology Galera Therapeutics, Inc GRECO-2: A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer
Chandrikha Chandrasekharan Internal Medicine Genentech, Inc A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab with or without Tiragolumab (Anti-Tigit Antibody) in Patients with Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Pashtoon Kasi Internal Medicine Elicio Therapeutics, Inc First in Human Phase 1 /2 Trial of ELI-002 Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
Mohammed Milhem Internal Medicine Checkmate Pharmaceuticals A Randomized, Open-Label, Active-Control, Phase 2/3 Study of First-Line Intratumoral CMP-001 in Combination with Intravenous Nivolumab Compared to Monotherapy in Subjects with Unresectable or Metastatic Melanoma
Michael Shy Neurology Charcot-Marie-Tooth Association CMT2A Biomarkers and Outcome Measures
Jack Stapleton Internal Medicine Iowa Department of Public Health HIV Core and Medical Support Services
Michael Tomasson Internal Medicine Pfizer, Inc An Open-Label, Multicenter, Non-Randomized Phase 2 Study of PF 06863135 Monotherapy in Participants with Multiple Myeloma who are Refractory to at Least One Proteasome Inhibitor, One Immunomodulatory Drug and One Anti-CD38 Antibody

Top of Page

MAY 2021

New Federal Awards

Dale Abel
Val Sheffield
Internal Medicine NIH R01 - 5 years Modulating ROS by electromagnetic fields to treat Type 2 Diabetes
Craig Ellermeier
David Weiss
Microbiology and Immunology NIH R01 - 5 years Cell Envelope Biogenesis in Clostridioides difficile
Chad Grueter Internal Medicine NIH R03 - 1 year Cdk19-dependent transcriptional mechanisms in cardiac hypertrophy
Lyndsay Harshman Pediatrics NIH R01 - 5 years Brain anatomical imaging and neurocognition in pediatric kidney disease (BRAIN KID)
Loreen Herwaldt Internal Medicine CDC U54 - 5 years Infection Prevention and Antimicrobial Stewardship: Minding the Gaps: The Iowa Prevention Epicenter
Vincent Magnotta Radiology NIH S10 - 1 year University of Iowa - 3T ESP MRI Scanner
Li Wu Microbiology and Immunology NIH R21 - 2 years Epitranscriptomic m6A profile of SARS-CoV-2-infected human lung epithelial cells

Other Awards

John Bernat Pediatrics AVROBIO, Inc Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-02 For Subjects with Type 1 Gaucher Disease
Douglas Laux Internal Medicine Checkmate Pharmaceuticals Intratumoral CMp-001 In Combo w/ Intravenous Pembrolizumab in Subjects with Head and Neck Squamous Cell Carcinoma
Antonio Sanchez Internal Medicine Boehringer Ingelheim Pharmaceuticals, Inc A trial to evaluate efficacy, safety and tolerability of multiple subcutaneous doses of BI 456906 in patients with NASH and fibrosis
Jack Stapleton Internal Medicine AbbVie, Inc Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ABBV-382 in Persons Living with HIV-1 (PLWH)
Tomohiro Tanaka Internal Medicine GlaxoSmithKline LLC Sequential GSK32288363 and Peginterferon Treatment in Participants with Chronic Hepatitis B Virus (B-Together)
Anne-Sophie Wattiez Molecular Phyusiology and Biophysics Schedule 1 Therapeutics Optimization of Cannabinoids for Development as FDA-Approved Migraine Therapeutics

Top of Page

APRIL 2021

Competitive Renewals

Ted Abel Neuroscience and Pharmacology NIH R01 - 5 years Epigenetic Mechanisms of Memory Storage
George Weiner Internal Medicine NIH P30 - 5 years Cancer Center Support Grant (CCSG)

New Federal Awards

Jennifer Bermick Pediatrics NIH R01 - 4 years Understanding the role of histone 3 lysine 4 trimethylation in neonatal innate immune development under normal and inflammatory conditions
Snehajyoti Chatterjee Neuroscience and Pharmacology NIH K99 - 5 years Understanding the molecular mechanism of memory from single-cell gene expression to protein folding
Cui Huxing Neuroscience and Pharmacology NIH R01 - 4 years Decoding brain circuit underlying metabolic regulation of sleep-wake behavior
John Engelhardt
Andrew Norris
Anatomy and Cell Biology NIH RC2 - 3 years Early Pathogenesis of Cystic Fibrosis Related Diabetes
Dawn Quelle Neuroscience and Pharmacology NIH R01 - 5 years Role of RABL6A-PP2A in neuroendocrine tumors

Other Awards

Joseph Dillon
Yusuf Menda
Internal Medicine ITM Solucin GmbH Peptide Receptor Radionuclide Therapy with 177 Lu-Edotreotide Compared to Targeted Molecular Therapy
Arlene Drack Ophthalmology and Visual Sciences Foundation Fighting Blindness FFB Canada FFB Canada-Treatment of BBS10 in mouse Bbs10-/- model using Human BBS10 gene in 2 different vectors
Mary Beth Fasano Internal Medicine Benaroya Research Institute at Virginia Mason Systemic Allergic Reactions to SARS-CoV-2 Vaccination
Barcey Thurston Levy Family Medicine University of Massachusetts Medical School RADxAcceleRATeD study (Rapid Assessment of Technology for SARS-CoV-2 Detection)
Mohammed Milhem Internal Medicine Checkmate Pharmaceuticals Intratumoral CMP-001 In Combo w/ Intravenous Nivolumab in Unresectable or Metastic Melanoma
Ernesto Ruiz Duque Internal Medicine Alnylam Pharmaceuticals, Inc APOLLO-B: A Study to Evaluate Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
Michael Shy Neurology Charcot-Marie-Tooth Association CMT1X Biomarkers and Outcomes Measures
Grerk Sutamtewagul Internal Medicine Novartis Pharmaceuticals Corporation Azacitidine with or without MBG453 for patients with Myelodysplastic syndrome (MDS)
Yousef Zakharia Internal Medicine Incyte Biosciences International S.a.r.l. INCMGA00012, INCAGN02385, and INCAGN02390 in Participants with Select Advanced Malignancies

Top of Page

MARCH 2021

New Federal Awards

Jon Houtman
Steven Varga
Microbiology and Immunology NIH R21 - 2 years CD4 T cell intrinsic signaling defects during viral exhaustion
Nandakumar Narayanan Neurology NIH R01 - 5 years VTA dopamine neurons and cognitive symptoms of Parkinson's
Adam Mailloux Microbiology and Immunology NIH R21 - 1 year Autohistomagnetic Isolation of Tumor-reactive T-cells
Craig Ellermeier Microbiology and Immunology NIH R21 - 2 years Regulation of the C. difficile cell envelope by Two-component systems
Alexander Boyden Pathology NIH R21 - 2 years Role of B cell interactions in CNS autoimmune demyelination
Claudia Mello-Thoms Radiology NIH R01 - 5 years Satisfaction of Search in Breast Cancer Detection
Philip Polgreen Internal Medicine NIH R01 - 5 years Estimating the risk for and severity of respiratory infections attributable to CFTR hterozygosity
Prajwal Gurung Internal Medicine NIH R01 - 5 years Implicating a previously unknown Dectin1-RIPK2-CARD9 signaling in providing resistance against Leishmania major infection
Pamela Geyer Biochemistry and Molecular Biology NIH R21 - 2 years Aging and the nuclear lamina in mitotic stem cells

Other Awards

Chris Ahern Molecular Phyusiology and Biophysics University of Wisconsin-Madison Restoring vision with high-fidelity nonsense codon correction
Sabarish Ayyappan Internal Medicine Genmab US Inc A Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
Sabarish Ayyappan Internal Medicine Regeneron Pharmaceuticals, Inc A study to assess the anti-tumor activity and safety of regn1979, an anti-cd20 x anti-cd3 bispecific antibody, in patients with relapsed or refractory b-cell non-Hodgkin lymphoma
Linda Cadaret Internal Medicine Gossamer Bio, Inc Evaluating the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
John Engelhardt Anatomy and Cell Biology Cystic Fibrosis Foundation Development of Cystic Fibrosis Models in the Ferret
Muhammad Furqan Internal Medicine Inhibrx, Inc A Phase 1 Study of INBRX-106 in Subjects with Locally Advanced or Metastatic Solid Tumors
Nicholas Mohr Anesthesia Vanderbilt University Medical Center COVID: Adult Inpatient SARS-CoV-2 Vaccine Effectiveness Surveillance
Varun Monga Internal Medicine Pfizer, Inc A trial evaluating pharmacokinetics, safety and efficacy of pf 07284890 (arry 461) in participants with BRAF v600 mutant solid tumors with and without brain involvement
Douglas Van Daele Otolaryngology Nyxoah SA Assessing the safety and effectiveness of the GenioTM dual-sided hypoglossal nerve stimulation system for the treatment of obsructive sleep apnea in adult subjects (DREAM)

Top of Page

FEBRUARY 2021

New Federal Awards

Jordan Schulz Psychiatry NIH K23 - 5 years Autonomic Dysfunction as Early Pathologic Feature of Huntington's Disease
Ron Weigel
Tiandao Li
Junlin Liao
Surgery DoD, CDMRP - 3 years SUMO Inhibition Represses Mammary Oncogenesis Through Etv1

Other New Awards

Camille Dunn-Johnson Otolaryngology MED-EL Corporation Single-Sided Deafness and Asymmetric Hearing Loss
John Engelhardt Anatomy and Cell Biology Cystic Fibrosis Foundation Regenerative Properties of Airway Submucosal Gland Stem Cell Niches
Douglas Laux Internal Medicine Replimune, Inc Cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaeneous squamous cell carcinoma
Enrique Leira Neurology Massachusetts General Hospital StokeNet: Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on Recovery (DISCOVERY)
Varun Monga Internal Medicine Medical College of Wisconsin Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as having CDK Pathway Alteration (BOAST)
Muhammad Furqan Internal Medicine Hoosier Cancer Research Network, Inc Chemo-immunotherapy Followed by Combo of Durvalumab and ATRi in Treatment Naïve Patients with Extensive Stage Small Cell Lung Cancer
Muhammad Furqan Internal Medicine Bristol-Myers Squibb Company First-in-human of BMS-986258 Alone and in Combo with Nivolumab in Advanced Tumors
Muhammad Furqan Internal Medicine Aprea Therapeutics APR-246 in Combination with Pembrolizumab in Subjects with Solid Tumor Malignancies
Lucy Wibbenmeyer Surgery Avita Medical Americas, LLC Regenerative Epidermal Suspension Prepared with the RECELL Device Compared to Standard of Care Dressings for Treatment of Partial
Pat Winokur Internal Medicine Sanofi Pasteur, Inc Immunogenicity and Safety of the First-in-Human SARS-CoV-2 mRNA Vaccine Formulation in Healthy Adults 18 Years of Age and Older

Top of Page

JANUARY 2021

New Federal Awards

Jennifer Bermick Pediatrics NIH R01 transfer - 5 years Targeting iron to improve outcomes in neonatal Escherichia coli sepsis
Zizhen Kang Pathology NIH R01 transfer - 2 years Integration of IL-17 and notch signaling in the pathogenesis of CNS inflammation
Stanely Perlman Microbiology and Immunology NIH T32 - 5 years Training in Molecular Virology, Viral Pathogenesis and Viral Vectors
Jon Resch Neuroscience and Pharmacology NIH R00 - 3 years Central Regulation of sodium appetite via synergistic action of RAAS-sensitive neurons
Shunguang Wei Internal Medicine NIH R01 - 4 years Novel Role of Interleukin-17 in Sympathetic Activation in Heart Failure

Other Awards 

Alejandro Comellas Internal Medicine Regeneron Pharmaceuticals, Inc The virologic efficacy of REGN10933+REGN10987 across different dose regimens in outpatients with SARS-CoV-2
Muhammad Furqan Internal Medicine PPD Investigator Services, LLC Autologous T-Cells expressing enhanced TCRs specific for NY-ESO-1/LAGE-1a alone or in combo with pembrolizumab
Margarida Magalhaes-Silverman Internal Medicine Marker Therapeutics, Inc Donor-derived multi-tumor-associated antigen-specific T Cells administered to patients with AML following hematopoietic stem cell transplantation
Philip Polgreen Internal Medicine University of Maryland Gathering new contact network data to inform interventions designed to Decrease the Spread of COVID-19
Antonio Sanchez Internal Medicine Merck Sharp & Dohme Corp Efficacy and Safety of MK-3655 in Individuals with Pre-cirrhotic Nonalcoholic Steatohepatitis

Top of Page